Screener
CytomX Therapeutics CTMX PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts receivable | 37,494 | 2,013 |
| Prepaid expenses and other current assets | 4,464 | 4,856 |
| Total current assets | 373,155 | 143,921 |
| Property and equipment, net | 1,079 | 1,304 |
| Intangible assets, net | 365 | 438 |
| Goodwill | 949 | 949 |
| Restricted cash | 610 | 1,527 |
| Operating lease right-of-use asset | 5,037 | 3,396 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's PP&E (net)?
- CytomX Therapeutics (CTMX) reported PP&E (net) of $1.08M in Q2 2026.
- How has CytomX Therapeutics's PP&E (net) changed year-over-year?
- CytomX Therapeutics's PP&E (net) decreased by 44.6% year-over-year, from $1.95M to $1.08M.
- What is the long-term trend for CytomX Therapeutics's PP&E (net)?
- Over 5 years (2020 to 2025), CytomX Therapeutics's PP&E (net) has grown at a -28.4% compound annual growth rate (CAGR), from $6.95M to $1.3M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about CytomX Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude